Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The Chinese fibromyalgia market is witnessing a surge in awareness about the condition among healthcare professionals and the general population. Increased recognition of fibromyalgia symptoms and diagnostic criteria has led to more accurate diagnoses.
There's a noticeable uptick in the incidence of fibromyalgia cases across China. Factors such as changing lifestyles, urbanization, and improved healthcare access contribute to the growing number of reported cases.
Now a thriving landscape of fibromyalgia management therapies can be seen at the haymarket. In the case of Traditional Chinese Medicine (TCM), there are healing methods that are broadly subscribed with regular Western treatment, e.g. acupuncture, medicinal herbs.
Along with this, pharmaceutical institutions clinching their pockets into research and development programs providing new medications solely for treating fibromyalgia symptoms appear in a wave. These medications will be used to deal with pain, make fatigue better and help with having good sleep.
Due to the digital health technology dominating the areas related with fibromyalgia management, integration is growing. Mobile apps, wearable gadgets, and telemedicine platforms ensure that patients can track their condition remotely, learn more using on-line resources in a convenient format, communicate with healthcare specialists in the absence of physical meetings with them.
Actually, there has emerged thefully-functioning system of patient advocacy groups and support networks tasked to give people more insight into fibromyalgia in China. These groups have been executing a significant role in providing tools, instruction and emotional assistance to the people with the illness.
The fiber malehahiotic landscape in China is continuing changing, the ongoing study be will focused on the underlying mechanisms of the condition. Fruitful joint efforts of academia, hospitals, and businesses are behind advanced research, new treatment methods, and clinical practices.
It is a rather positive trend which is observable due to Chinese came up with a number of measures to modernize the medical infrastructure of the country on the fibromyalgia market. Such investments in healthcare facilities, competent personnel and specialized clinics bring about greater accessibility to both medical diagnosis and treatment for patients.
The public health strategies that contribute positively to early detection and management of fibromyalgia have started gaining front row seats. Available programs developed and co-financed by government to increase public knowledge about the shortlist of early symptoms, signs and credible resources for both patients and caregivers.
Medical progress notwithstanding, equality of fibromyalgia treatment and support services is oftentimes hard to come by, even within a streamlined and uniform healthcare structure in the country. In the time set as deadline is still hard to achieve full healthcare equality between the urban and rural areas, also middle class still cannot afford some treatments expenses.
There's a growing recognition of the importance of holistic approaches in fibromyalgia management. Integrative therapies combining conventional medicine with lifestyle modifications, stress management techniques, and mind-body interventions are increasingly favored by patients and healthcare providers alike.
Intensifying competition among pharmaceutical companies and healthcare providers in the fibromyalgia market is driving innovation and pushing for the development of more effective treatment options and patient-centric care models.
Chinese Fibromyalgia Market Highlights:
Chinese Fibromyalgia Market Overview
Chinese Fibromyalgia Market Size was valued at USD 13.45 Billion in 2023. The Global Chinese Fibromyalgia industry is projected to grow from USD 13.93 Billion in 2024 to USD 21.53 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 14.32% during the forecast period (2024 - 2032).
Fibromyalgia syndrome is a condition characterized by widespread musculoskeletal pain. Patients with fibromyalgia may also have muscle stiffness, increased sensitivity to pain, problems with mental processes, fatigue, irritable bowel syndrome (IBS), and others. As symptoms of fibromyalgia syndrome mimic other chronic diseases, therefore its diagnosis takes a long time. According to a study published in Arthritis Research & Therapy journal in 2017, in Taiwan, the risk of coronary heart disease in fibromyalgia patients was 47% higher than in the general population. For fibromyalgia to be diagnosed, the differential diagnosis is most commonly used. Other diagnostic procedures, such as laboratory evaluations are also used.
Notably, increasing cases of rheumatic diseases and growing geriatric population are the key factors driving the Chinese fibromyalgia market. According to the study published in Aging Clinical and Experimental Research in 2014, fibromyalgia syndrome can affect people of all age group, with the high prevalence in the elderly population as the geriatric population is more vulnerable towards pain, reduced mobility, and sleep disruption. In the general population, the prevalence of fibromyalgia increases by 2% at the age of 20 to 8% at the age of 70.
Growing awareness among the population, and rising incidences of traumatic stress and road accidents are also fueling the market growth. According to a study published in Pain Research and Management journal, in 2014, it was found that physical trauma is followed by fibromyalgia syndrome. In this study, conducted with a specific cohort of individuals involved in a motor vehicle collision, found that 8% of individuals developed widespread chronic pain. Widespread chronic pain characterizes fibromyalgia.
However, difficulty in diagnosis may hinder the growth of the market over the forecast period. Fibromyalgia can’t be easily confirmed as the condition is commonly expressed with many other accompanying chronic disorders such as rheumatic diseases, neurological disorders, mental health problems, and others
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with an extensive product portfolio and pipeline, announced positive results from its clinical pharmacokinetic (PK) bridging study of Tonmya™ (also known as TNX-102 SL, cyclobenzaprine HCl sublingual tablets) in healthy adult male and female ethnic Japanese and Chinese volunteers in February 2024.
A Sheffield woman who claimed to have perfect health after curing herself of chronic fatigue will appear on Dragons’ Den in January 2024. Giselle Boxer was working at one of the top advertising agencies when she was twenty-six years old; that is when M.E (myalgic encephalomyelitis) was diagnosed.
There has been massive research coverage and news about various aspects of fibromyalgia in China since July 2024. According to a recent cross-sectional study examining demography characteristics as well as clinical features among Chinese fibromyalgia patients, these studies concluded that fibromyalgia significantly affects the quality of life and is often accompanied by other health problems such as depression and chronic fatigue.
Intended Audience
- Pharmaceutical Companies
- Hospitals & Clinics
- Research and Development (R&D) Companies
- Government Research Institute
- Academic Institutes and Universities
Figure: Chinese Fibromyalgia Market by Diagnosis market share, 2016 (%)
Sources: Annual reports, Press release, White paper, Company presentation
Chinese Fibromyalgia Market Segmentat Insights
The chinese fibromyalgia market is segmented on the basis of diagnosis, treatment, and end-user.
On the basis of the diagnosis, the chinese fibromyalgia market is classified into laboratory evaluation and presence of central sensitization.
On the basis of the treatment, the chinese fibromyalgia market is segmented into targeted treatment and symptomatic treatment.
On the basis of the end-users, the chinese fibromyalgia market is segmented into hospitals, clinics, diagnostic centers, and others.
Research Methodology
Sources: Annual reports, Press release, White paper, and Company presentation
Key Findings
- The Chinese fibromyalgia market is expected to reach USD 3,079.1 million by 2022 at a CAGR of 18.7%
- On the basis of the diagnosis, the laboratory evaluation segment is expected to command the largest market share of 77.2% over the review period, and it is also expected to grow at the fastest CAGR of 19.1% during the forecast period 2017-2022
- On the basis of the treatment, the symptomatic treatment segment is expected to command the largest market share of 68.6% over the review period, and targeted treatment is expected to grow at the fastest CAGR of 19.2% during the forecast period 2017-2022
- South Central China holds the largest share of the Chinese fibromyalgia market and is expected to reach USD 785.3 million by 2022
- North China is the fastest growing market, which is expected to grow at a CAGR of 19.2% over the forecast period 2017-2022
Chinese Fibromyalgia Market Regional Analysis
South Central China accounted for the major share of the market owing to the rising prevalence of fibromyalgia in this region. Rising cases of chronic rheumatic diseases are also capable of fuelling the fibromyalgia market in China. Prevalence of rheumatoid arthritis is around 0.35%, with the significantly higher rate in Northern China as compared to the Southern part.
The rising healthcare expenditure is also propelling the growth of the market. In China, the total expenditure on health per capita in 2014 was USD 731, as per the World Health Organization (WHO) in 2015. The health expenditure in China grew at a rate of 11.6% per year, suggested by a study published in BMC Health Services Research journal in 2017. This rate is much faster than the growth of the country’s economy, i.e. 9.9% per year.
Chinese Fibromyalgia Market Key Players
Some of key the players in the chinese fibromyalgia market are
- Pfizer,
- Roche,
- Astellas Pharma,
- Eli Lilly and Company,
- Johnson & Johnson Services, Inc.,
- SANOFI,
- Bayer AG,
- GlaxoSmithKline,
- AstraZeneca,
- AbbVie,
- ALLERGAN,
- Boehringer Ingelheim,
- Cephalon, Inc.,
- Vertical Pharmaceuticals,
- Sunovion Pharms Inc,
- Jazz Pharmaceuticals,
- ABBOTT,
- NOVARTIS, and
- others.
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
